Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Women Exec Ratio 14.7% among TSE Prime Drug Makers, Wholesalers; Astellas Leads the Way at 30%
June 2, 2023
- CSL Behring Launches App to Manage HAE Records
June 2, 2023
- Japan Pharma Market Grows for 2 Years Running with 2.6% Rise in FY2022: IQVIA
June 2, 2023
- Shionogi Shoots for Doubling Revenue to 800 Billion Yen by FY2030
June 2, 2023
- Ferring Japan Recalling Fertility Drug Lutinus after Bacteria Detection
June 2, 2023
- Shionogi to End Crestor Sales, AstraZeneca to Go Solo
June 2, 2023
- Pharma Companies in Japan Raising Retirement Age, Extending Rehiring: Jiho Poll
June 1, 2023
- Nipro Pharma Submits Business Improvement Plan after GMP Issues
June 1, 2023
- AnGes Seeks Full Approval for Gene Therapy Collategene in Japan
June 1, 2023
- Braftovi/Mektovi Filed for Thyroid Cancer in Japan: Ono
June 1, 2023
- Maruho’s Bepio Lotion Hits Japan Pharmacy Shelves
June 1, 2023
- AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
- Jeremy Grossas to Head Up Merck Biopharma Japan
May 30, 2023
- Nobelpharma Gets EU Nod for Hyftor
May 30, 2023
- Pfizer Japan Files RSV Vaccine for 60 Years of Age and Older
May 29, 2023
- Chugai’s FoundationOne Liquid Wins Approval as Tabrecta CDx
May 29, 2023
- Seikagaku Nets Positive Data in Additional US PIII for Herniated Disk Drug
May 29, 2023
- Hutchmed’s Colorectal Cancer Med Gets FDA’s Priority Review: Takeda
May 29, 2023
- PharmaEssentia’s 1st Product to Hit Japan Market on June 1
May 29, 2023
- Ex-Takeda Exec Motoi Muraki to Take Helm at ViiV Japan
May 26, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…